Skip to content
ChickenStockChickenStock
Research068760
Celltrion Pharm logo

Celltrion Pharm (068760) stock

KOSDAQ · Pharmaceuticals

KRW 40,400-1.70%(-700)

As of the Nov 16 regular-session close (Korea)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

41.94x

P/B

4.00x

P/S

3.11x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Separate · Filed Aug 14, 2026KRW 153.3 billionKRW 19.3 billionKRW 13.7 billion+16.8%
Q1 2026Separate · Filed May 15, 2026KRW 132.1 billionKRW 12.9 billionKRW 8.8 billion+17.4%
Q4 2025Separate · Filed Mar 16, 2026KRW 154.4 billionKRW 13.7 billionKRW 8.9 billion—
Q3 2025Separate · Filed Nov 14, 2025KRW 138.2 billionKRW 16.1 billionKRW 11.5 billion+7.8%
Q2 2025Separate · Filed Aug 14, 2025KRW 131.3 billionKRW 15.5 billionKRW 11.1 billion+12.1%
Q1 2025Separate · Filed May 15, 2025KRW 112.5 billionKRW 10.7 billionKRW 7.3 billion+16.0%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Separate · Filed Mar 16, 2026KRW 536.4 billionKRW 56.1 billionKRW 38.8 billion—
FY2024Separate · Filed Mar 24, 2025KRW 477.8 billionKRW 37.2 billionKRW 22 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
5.33%
Of trading value on Nov 13, 2026
Short-sale value
KRW 300 million
Previous 20-day average 3.83%
Net short position
69,654 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
1,900,371 shares
As of Nov 13, 2026 · 4.28% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20265.33%KRW 300 million
Nov 12, 20261.10%KRW 50 million
Nov 11, 20260.23%KRW 30 million
Nov 10, 20261.07%KRW 70 million
Nov 9, 20264.08%KRW 340 million
Nov 6, 20261.16%KRW 80 million
Nov 5, 20262.33%KRW 220 million
Nov 4, 20268.91%KRW 360 million
Nov 3, 20264.35%KRW 90 million
Nov 2, 20266.14%KRW 70 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Celltrion Pharm (068760) stock information

KOSDAQ

Celltrion Pharm (068760) is listed on KOSDAQ. Its market capitalization is about KRW 1.8 trillion. On trailing-twelve-month earnings the P/E ratio is 41.94, and the P/B ratio is 4. Return on equity is 9.5%. These figures are computed in-house from official filings and are reference information only.

Celltrion Pharm — frequently asked questions

What is the P/E ratio of Celltrion Pharm (068760)?
On a trailing-twelve-month basis, 068760 trades at a P/E ratio of 41.94. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Celltrion Pharm?
068760 has a market capitalization of about KRW 1.8 trillion. The figure moves with the share price and is refreshed each trading day.
Does Celltrion Pharm pay a dividend?
068760 has a dividend yield of about 0.49%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.